Ketoconzole microbiology: Difference between revisions
Ahmed Zaghw (talk | contribs) (Created page with "__NOTOC__ {{Ketoconazole}} {{CMG}}; {{AE}} {{AZ}} ==Microbiology== ===Mechanism of Action==== Ketoconazole blocks the synthesis of ergosterol, a key component of the funga...") |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
{{Ketoconazole}} | {{Ketoconazole}} | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Microbiology== | ==Microbiology== | ||
===Mechanism of Action | ===Mechanism of Action=== | ||
Ketoconazole blocks the synthesis of ergosterol, a key component of the fungal cell membrane, through the inhibition of cytochrome P-450 dependent enzyme lanosterol 14α-demethylase responsible for the conversion of lanosterol to ergosterol in the fungal cell membrane. This results in an accumulation of methylated sterol precursors and a depletion of ergosterol within the cell membrane thus weakening the structure and function of the fungal cell membrane. | Ketoconazole blocks the synthesis of ergosterol, a key component of the fungal cell membrane, through the inhibition of cytochrome P-450 dependent enzyme lanosterol 14α-demethylase responsible for the conversion of lanosterol to ergosterol in the fungal cell membrane. This results in an accumulation of methylated sterol precursors and a depletion of ergosterol within the cell membrane thus weakening the structure and function of the fungal cell membrane. | ||
===Activity In Vitro | ===Activity In Vitro and In Vivo=== | ||
Ketoconazole tablets USP, 200 mg are active against clinical infections with Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum,Paracoccidioides brasiliensis.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = KETOCONAZOLE TABLET [TARO PHARMACEUTICALS U.S.A., INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ca815a8-bccb-4ee2-a042-922373329cae | publisher = | date = | accessdate = }}</ref> | Ketoconazole tablets USP, 200 mg are active against clinical infections with [[Blastomyces]] dermatitidis, [[Coccidioides]] immitis, [[Histoplasma]] capsulatum, [[Paracoccidioides brasiliensis|Paracoccidioides brasiliensis]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = KETOCONAZOLE TABLET [TARO PHARMACEUTICALS U.S.A., INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ca815a8-bccb-4ee2-a042-922373329cae | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Latest revision as of 07:15, 10 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Microbiology
Mechanism of Action
Ketoconazole blocks the synthesis of ergosterol, a key component of the fungal cell membrane, through the inhibition of cytochrome P-450 dependent enzyme lanosterol 14α-demethylase responsible for the conversion of lanosterol to ergosterol in the fungal cell membrane. This results in an accumulation of methylated sterol precursors and a depletion of ergosterol within the cell membrane thus weakening the structure and function of the fungal cell membrane.
Activity In Vitro and In Vivo
Ketoconazole tablets USP, 200 mg are active against clinical infections with Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, Paracoccidioides brasiliensis.[1]
References
Adapted from the FDA Package Insert.